ValuEngine cut shares of Fate Therapeutics (NASDAQ:FATE) from a hold rating to a sell rating in a report released on Friday morning.

A number of other analysts have also commented on FATE. Zacks Investment Research raised shares of Fate Therapeutics from a hold rating to a buy rating and set a $3.50 price objective for the company in a research note on Thursday, August 17th. Leerink Swann reiterated an outperform rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Friday, September 8th. HC Wainwright reiterated a buy rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Thursday, October 12th. Finally, BMO Capital Markets reiterated a buy rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $6.79.

Fate Therapeutics (FATE) traded down $0.01 during mid-day trading on Friday, reaching $4.39. 176,338 shares of the company’s stock were exchanged, compared to its average volume of 229,991. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a 52 week low of $2.40 and a 52 week high of $5.68.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.95 million. The firm’s revenue was up .0% compared to the same quarter last year. sell-side analysts predict that Fate Therapeutics will post -0.99 EPS for the current year.

In other news, insider Daniel D. Shoemaker sold 13,225 shares of the company’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel Cindy Tahl sold 8,091 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.85, for a total value of $31,150.35. The disclosure for this sale can be found here. 10.88% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Fate Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock worth $4,096,000 after buying an additional 108,602 shares during the last quarter. Morgan Stanley increased its holdings in Fate Therapeutics by 9.8% in the first quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after buying an additional 54,615 shares during the last quarter. State Street Corp acquired a new position in Fate Therapeutics in the second quarter worth approximately $1,437,000. Northern Trust Corp increased its holdings in Fate Therapeutics by 968.7% in the second quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock worth $1,193,000 after buying an additional 333,753 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Fate Therapeutics by 40.9% in the first quarter. Renaissance Technologies LLC now owns 295,700 shares of the biopharmaceutical company’s stock worth $1,345,000 after buying an additional 85,800 shares during the last quarter. Hedge funds and other institutional investors own 60.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Fate Therapeutics (FATE) Downgraded to “Sell” at ValuEngine” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/02/fate-therapeutics-fate-downgraded-to-sell-at-valuengine.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Stock Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related stocks with our FREE daily email newsletter.